Evidence map›Paper›PMID 29898878›Full record

ArticleBlood advances2018

Blood group

Emili Cid, Miyako Yamamoto, Fumiichiro Yamamoto

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. The Usefulness of Rare Blood Group Systems in the Risk Determination for Severe COVID-19.Pathophysiology : the official journal of the International Society for Pathophysiology · 2021
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Emili CidLaboratory of Immunohematology and Glycobiology, Josep Carreras Leukaemia Research Institute, and.ORCID 0000-0002-5025-352X
Miyako YamamotoLaboratory of Immunohematology and Glycobiology, Josep Carreras Leukaemia Research Institute, and.ORCID 0000-0001-9516-1402
Fumiichiro YamamotoLaboratory of Immunohematology and Glycobiology, Josep Carreras Leukaemia Research Institute, and.ORCID 0000-0001-9690-7034
Josep Carreras Leukaemia Research Institute · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blood group A/B glycosyltransferases (AT/BTs) and Forssman glycolipid synthase (FS) are encoded by the evolutionarily related

Indexed as

Amino Acid SubstitutionBlood Group AntigensN-AcetylgalactosaminyltransferasesABO Blood-Group SystemAnimalsChlorocebus aethiopsCOS CellsForssman AntigenGlycosyltransferasesHeLa CellsHumansTransfectionABO Blood-Group SystemBlood Group AntigensForssman AntigenGBGT1 protein, humangloboside alpha-N-acetylgalactosaminyltransferaseGlycosyltransferasesN-Acetylgalactosaminyltransferases

Identifiers

PMID29898878
PMCPMC6020805
OpenAlexW2808563795

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.